Browse Studies — Arctuva

Phase 1

A Phase I Study to Assess the Safety and Antitumor Activity of Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

Background: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that …

Recurrent Small Cell Lung CancerExtensive-Stage Small Cell Lung CancerSmall Cell Lung Cancer+6 more

Estimated

~$10 – $5,625

Find your next paid study

A Phase I Study to Assess the Safety and Antitumor Activity of Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC